


ABSTRACT OF THE DISCLOSURE

The specification discloses compounds selected from those of formula (I):



or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein
 5 R₂, m, A, Z₁, n, G₂, X₁, X₂, X₃, G₁, and R₁ are as defined in the specification, wherein the
 compound of formula (I) is not 6-(2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine)-benzoate,
 6-phenylthio-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine, 6-benzylsulphonyl-2,4-dioxo-
 3,4-dihydro-2H-1,3-benzothiazine, 6-benzophenone-2,4-dioxo-3,4-dihydro-2H-1,3-
 benzothiazine or 6-(2,4-dihydroxy)-benzophenone-2,4-dioxo-3,4-dihydro-2H-1,3-
 10 benzothiazine. The specification also discloses processes for preparing the compounds,
 pharmaceutical compositions comprising said compounds of formula (I) or a racemic form,
 isomer, N-oxide, or pharmaceutically acceptable salt thereof, and methods of treating
 diseases or disorders mediated by a MMP-13 enzyme or responsive to treatment with an
 inhibitor of a MMP-13 enzyme, comprising administering said compounds of formula (I)
 15 or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof.